Cited by 1,598Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchCancer Genomics and Diagnostics

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Open access

Bean, James, Brennan, Cameron, Shih, Jin-Yuan, Riely, Gregory, Viale, Agnes, Wang, Lu, Chitale, Dhananjay, Motoi, Noriko, Szoke, Janos, Broderick, Stephen, Balak, Marissa, Chang, Wen-Cheng, Yu, Chong-Jen, Gazdar, Adi, Pass, Harvey, Rusch, Valerie, Gerald, William, Huang, Shiu-Feng, Yang, Pan-Chyr, Miller, Vincent, Ladanyi, Marc, Yang, Chih-Hsin, Pao, William·2007·Proceedings of the National Academy of Sciences

DOI 10.1073/pnas.0710370104PMC PMC2409244

Open this paper in CoChat — free account

Abstract

In human lung adenocarcinomas harboring EGFR mutations, a second-site point mutation that substitutes methionine for threonine at position 790 (T790M) is associated with approximately half of cases of acquired resistance to the EGFR kinase inhibitors, gefitinib and erlotinib. To identify other potential mechanisms that contribute to disease progression, we used array-based comparative genomic hybridization (aCGH) to compare genomic profiles of EGFR mutant tumors from untreated patients with those from patients with acquired resistance. Among three loci demonstrating recurrent copy number alterations (CNAs) specific to the acquired resistance set, one contained the MET proto-oncogene. Collectively, analysis of tumor samples from multiple independent patient cohorts revealed that MET was amplified in tumors from 9 of 43 (21%) patients with acquired resistance but in only two tumors from 62 untreated patients (3%) (P = 0.007, Fisher's Exact test). Among 10 resistant tumors from the nine patients with MET amplification, 4 also harbored the EGFR(T790M) mutation. We also found that an existing EGFR mutant lung adenocarcinoma cell line, NCI-H820, harbors MET amplification in addition to a drug-sensitive EGFR mutation and the T790M change. Growth inhibition studies demonstrate that these cells are resistant to both erlotinib and an irreversible EGFR inhibitor (CL-387,785) but sensitive to a multikinase inhibitor (XL880) with potent activity against MET. Taken together, these data suggest that MET amplification occurs independently of EGFR(T790M) mutations and that MET may be a clinically relevant therapeutic target for some patients with acquired resistance to gefitinib or erlotinib.

Integrity signals

Registry

Crossref · 10.1073/pnas.0710370104

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Self-citation
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Self-citation
Met, metastasis, motility and more
Birchmeier, C., Birchmeier, W., Gherardi, E., & Woude, G. F. V. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1261 · Cited by 2,652
Circular binary segmentation for the analysis of array-based DNA copy number data
Olshen, A. B., Venkatraman, E. S., Lucito, R., & Wigler, M. H. (2004) · Biostatistics · doi:10.1093/biostatistics/kxh008 · Cited by 2,304
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas
Schmidt, L. S., Duh, F.-M. C., Chen, F., Kishida, T., Glenn, G. M., Choyke, P. L., Scherer, S. W., Zhuang, Z., Lubensky, I. A., Dean, M. C., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-68 · Cited by 1,517
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
Kwak, E. L., Sordella, R., Bell, D. W., Godin-Heymann, N., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Driscoll, D. R., Fidias, P. M., Lynch, T. J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502860102 · Cited by 966

Show all 37 references

Research works printed but not linked: 1

BA Weir, MS Woo, G Getz, S Perner, L. Ding, R Beroukhim, WM Lin, MA Province, A Kraja, L Johnson, et al. Nature, 10.1038. (2007).

Sorted by citations

Items 401–500 of 1,001

Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib
Xu, Y., Liu, H., Chen, J., & Zhou, Q. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.8.11881 · Cited by 79
Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer
Dienstmann, R., Dosso, S. D., Felip, E., & Tabernero, J. M. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.11.009 · Cited by 77
Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo
Mitchell, C., Yacoub, A., Hamed, H. A., Martin, A. P., Bareford, M. D., Eulitt, P. J., Chen, Y., Nephew, K. P., & Dent, P. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.9.13273 · Cited by 74
The role of cytology specimens in molecular testing of solid tumors: Techniques, limitations, and opportunities
Aisner, D. L., & Sams, S. B. (2012) · Diagnostic Cytopathology · doi:10.1002/dc.22820 · Cited by 76
Oligosaccharyltransferase: A Gatekeeper of Health and Tumor Progression
Harada, Y., Ohkawa, Y., Kizuka, Y., & Taniguchi, N. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20236074 · Cited by 76
Discovery of Dosimertinib, a Highly Potent, Selective, and Orally Efficacious Deuterated EGFR Targeting Clinical Candidate for the Treatment of Non-Small-Cell Lung Cancer
Meng, Y., Yu, B., Huang, H., Peng, Y., Li, E., Yao, Y., Song, C., Yu, W., Zhu, K., Wang, K., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02005 · Cited by 76
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR- Activating Mutation
Monica, S. L., Madeddu, D., Tiseo, M., Vivo, V., Galetti, M., Cretella, D., Bonelli, M. A., Fumarola, C., Cavazzoni, A., Falco, A., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.03.006 · Cited by 75
Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC)
Langer, C. J., Mok, T. S. K., & Postmus, P. E. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.05.003 · Cited by 75
Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation
He, S., Yin, T., Li, D., Gao, X., Wan, Y., Ma, X., Ye, T., Guo, F., Sun, J., Lin, Z., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-186 · Cited by 76
The Met oncogene and basal-like breast cancer: another culprit to watch out for?
Gastaldi, S., Comoglio, P. M., & Trusolino, L. (2010) · Breast Cancer Research · doi:10.1186/bcr2617 · Cited by 78
EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer
Wang, Z., & Fang, S. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s69690 · Cited by 80
Integrin beta1 over‐expression associates with resistance to tyrosine kinase inhibitor gefitinib in non‐small cell lung cancer
Ju, L., Zhou, C., Li, W., & Yan, L. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22888 · Cited by 75
Biology of MET: a double life between normal tissue repair and tumor progression.
Petrini, I. (2015) · PubMed Central · doi:10.3978/j.issn.2305-5839.2015.03.58 · Cited by 75
Synergistic Effects of Foretinib with HER-Targeted Agents in MET and HER1- or HER2-Coactivated Tumor Cells
Liu, L., Shi, H., Liu, Y., Anderson, A. E., Peterson, J. J., Greger, J., Martin, A., & Gilmer, T. M. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0698 · Cited by 74
Targeting HGF/c-MET Axis in Pancreatic Cancer
Pothula, S. P., Xu, Z., Goldstein, D., Pirola, R. C., Wilson, J. S., & Apte, M. V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239170 · Cited by 74
Inhibition of DCLK1 sensitizes resistant lung adenocarcinomas to EGFR-TKI through suppression of Wnt/β-Catenin activity and cancer stemness
Yan, R., Fan, X., Xiao, Z., Liu, H., Huang, X., Liu, J., Zhang, S., Yao, J., An, G., & Ge, Y. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.01.030 · Cited by 75
Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody
Lee, J. M., Kim, B., Lee, S. B., Jeong, Y., Oh, Y. M., Song, Y.-J., Jung, S. H., Choi, J., Lee, S., Cheong, K. H., et al. (2012) · Oncogene · doi:10.1038/onc.2012.551 · Cited by 74
MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib
Huang, M.-H., Lee, J., Chang, Y., Tsai, H.-H., Lin, Y., Lin, A. M.-Y., & Yang, J. C. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.09.002 · Cited by 74
Advances on EGFR mutation for lung cancer.
Metro, G., & Crinò, L. (2012) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2011.12.01 · Cited by 73
Targeting EGFR resistance networks in head and neck cancer
Ratushny, V., Astsaturov, I. A., Burtness, B. A., Golemis, E. A., & Silverman, J. S. (2009) · Cellular Signalling · doi:10.1016/j.cellsig.2009.02.021 · Cited by 76
Deciphering the Role of Forkhead Transcription Factors in Cancer Therapy
Yang, J.-Y., & Hung, M. (2011) · Current Drug Targets · doi:10.2174/138945011796150299 · Cited by 75
Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer
Riely, G. J. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318174e96e · Cited by 74
Self-citation
TAK-701, a Humanized Monoclonal Antibody to Hepatocyte Growth Factor, Reverses Gefitinib Resistance Induced by Tumor-Derived HGF in Non–Small Cell Lung Cancer with an EGFR Mutation
Okamoto, W., Okamoto, I., Tanaka, K., Hatashita, E., Yamada, Y., Kuwata, K., Yamaguchi, H., Arao, T., Nishio, K., Fukuoka, M., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0481 · Cited by 74
The Role of MET Receptor Tyrosine Kinase in Non-Small Cell Lung Cancer and Clinical Development of Targeted Anti-MET Agents
Robinson, K. W., & Sandler, A. B. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0262 · Cited by 75
Assessment of Epidermal Growth Factor Receptor and K-Ras Mutation Status in Cytological Stained Smears of Non-Small Cell Lung Cancer Patients: Correlation with Clinical Outcomes
Lozano, M. D., Zulueta, J. J., Echeveste, J. I., Gúrpide, A., Seijo, L. M., Martín‐Algarra, S., del Barrio, A., Pı́o, R., Idoate, M. A., Labiano, T., et al. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0155 · Cited by 74
Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells
Lee, Y., Wang, Y., James, M. A., Jeong, J. H., & You, M. (2015) · Molecular Carcinogenesis · doi:10.1002/mc.22342 · Cited by 76
Blockade of Hedgehog Signaling Synergistically Increases Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Cell Lines
Bai, X., Zhang, X., Yang, S., An, S., Chen, Z., Su, J., Xie, Z., Gou, L.-Y., & Wu, Y.-L. L. C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149370 · Cited by 72
A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer
Yang, J., Fang, J., Shu, Y., Chang, J., Chen, G., He, J., Li, W., Liu, X., Yang, N., Zhou, C., et al. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-01010-4 · Cited by 72
Genetic and epigenetic changes in lung carcinoma and their clinical implications
Wen, J., Fu, J., Zhang, W., & Guo, M. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.46 · Cited by 77
Biomarkers in Lung Adenocarcinoma: A Decade of Progress
Sholl, L. M. (2014) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2014-0128-ra · Cited by 75
Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers.
Adjei, A. A., Schwartz, B., & Garmey, E. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0380 · Cited by 73
Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer
Ji, W., Choi, C., Rho, J. K., Jang, S. J., Park, Y. S., Chun, S., Kim, W. S., Lee, J., Kim, S., Lee, D. H., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-606 · Cited by 72
Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor–Driven Lung Adenocarcinoma
Maity, T. K., Venugopalan, A., Linnoila, I., Cultraro, C. M., Giannakou, A., Nemati, R., Zhang, X., Webster, J. D., Ritt, D., Ghosal, S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0750 · Cited by 73
Ferroptosis and Tumor Drug Resistance: Current Status and Major Challenges
Nie, Z., Chen, M., Gao, Y., Huang, D., Cao, H., Peng, Y., Guo, N., Wang, F., & Zhang, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.879317 · Cited by 83
c-Met signaling in the development of tumorigenesis and chemoresistance: Potential applications in pancreatic cancer
Delitto, D. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i26.8458 · Cited by 72
Profiling phospho-signaling networks in breast cancer using reverse-phase protein arrays
Gujral, T. S., Karp, R. L., Finski, A., Chan, M. M., Schwartz, P. E., MacBeath, G., & Sorger, P. K. (2012) · Oncogene · doi:10.1038/onc.2012.378 · Cited by 71
MET/HGF pathway activation as a paradigm of resistance to targeted therapies
Ko, B., He, T., Gadgeel, S. M., & Halmos, B. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2016.12.09 · Cited by 71
Adaptive stress signaling in targeted cancer therapy resistance
Pazarentzos, E., & Bivona, T. G. (2015) · Oncogene · doi:10.1038/onc.2015.26 · Cited by 73
Differentiated regulation of immune-response related genes between LUAD and LUSC subtypes of lung cancers
Chen, M., Liu, X., Du, J., Wang, X., & Xia, L. (2016) · Oncotarget · doi:10.18632/oncotarget.13346 · Cited by 70
MET Pathway as a Therapeutic Target
Kim, E. S., & Salgia, R. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31819d6f91 · Cited by 71
A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways
Romaniello, D., Mazzeo, L., Mancini, M., Marrocco, I., Noronha, A., Kreitman, M., Srivastava, S., Ghosh, S., Lindzen, M., Salame, T., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0450 · Cited by 70
Targeting the EGFR and the PKB pathway in cancer
Klein, S., & Levitzki, A. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.12.006 · Cited by 70
MET molecular mechanisms and therapies in lung cancer
Lawrence, R. E., & Salgia, R. (2010) · Cell Adhesion & Migration · doi:10.4161/cam.4.1.10973 · Cited by 70
Targeting the Met signaling pathway in renal cancer
Giubellino, A., Linehan, W. M., & Bottaro, D. P. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.43 · Cited by 71
CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers
Cheng, M. M., Quail, M. R., Gingrich, D. E., Ott, G. R., Lü, L., Wan, W., Albom, M. S., Angeles, T. S., Aimone, L. D., Cristofani, F., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0776 · Cited by 70
TR1801‐ADC: a highly potent cMet antibody–drug conjugate with high activity in patient‐derived xenograft models of solid tumors
Gymnopoulos, M., Betancourt, O., Blot, V., Fujita, R., Galvan, D., Lieuw, V., Nguyen, S., Snedden, J., Stewart, C., Villicana, J., et al. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12600 · Cited by 69
Drug resistance mechanisms and progress in the treatment of EGFR‑mutated lung adenocarcinoma (Review)
Sun, R., Hou, Z., Zhang, Y., & Jiang, B. (2022) · Oncology Letters · doi:10.3892/ol.2022.13528 · Cited by 77
Clinical Significance of BIM Deletion Polymorphism in Non–Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation
Isobe, K., Hata, Y., Tochigi, N., Kaburaki, K., Kobayashi, H., Makino, T., Otsuka, H., Sato, F., Ishida, F., Kikuchi, N., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000125 · Cited by 70
Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib
Hirsh, V. (2015) · BioDrugs · doi:10.1007/s40259-015-0130-9 · Cited by 72
Anticancer Effects of Paris Saponins by Apoptosis and PI3K/AKT Pathway in Gefitinib-Resistant Non-Small Cell Lung Cancer
Zhu, X., Jiang, H., Li, J., Ji, X., & Fei, Z. (2016) · Medical Science Monitor · doi:10.12659/msm.898558 · Cited by 68
Coactivation of Receptor Tyrosine Kinases in Malignant Mesothelioma as a Rationale for Combination Targeted Therapy
Brevet, M., Shimizu, S., Bott, M. J., Shukla, N. N., Zhou, Q., Olshen, A. B., Rusch, V. W., & Ladanyi, M. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318215a07d · Cited by 68
Self-citation
Quinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT, NF-κB, and Cell-Cycle Progression in Non–Small Cell Lung Cancer
Dermawan, J. K. T., Gurova, K. V., Pink, J. J., Dowlati, A., De, S., Narla, G., Sharma, N., & Stark, G. R. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0013 · Cited by 68
Inhibition of Tumor Growth and Metastasis in Non–Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET
Wu, W., Chen, B., Credille, K. M., Manro, J. R., Peek, V. L., Donoho, G. P., Yan, L., Wijsman, J. A., Yan, S.-C. B., & Walgren, R. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1758 · Cited by 68
Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients
Inoue, A., Yoshida, K., Morita, S., Imamura, F., Seto, T., Okamoto, I., Nakagawa, K., Yamamoto, N., Muto, S., & Fukuoka, M. (2016) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyw014 · Cited by 69
A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer
Rosen, L. S., Goldman, J. W., Algazi, A. P., Turner, P. K., Moser, B. A., Hu, T., Wang, X. A., TUTTLE, J. L., Wacheck, V., Wooldridge, J. E., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1418 · Cited by 68
A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity
Castoldi, R., Ecker, V., Wiehle, L., Majety, M., Busl-Schuller, R., Asmussen, M., Nopora, A., Jucknischke, U., Osl, F., Kobold, S., et al. (2013) · Oncogene · doi:10.1038/onc.2013.245 · Cited by 67
Phase 1 study of capmatinib in MET‐positive solid tumor patients: Dose escalation and expansion of selected cohorts
Bang, Y., Su, W., Schüler, M., Nam, D., Lim, W. T., Bauer, T. M., Azaro, A., Poon, R. T. P., Hong, D. S., Lin, C., et al. (2019) · Cancer Science · doi:10.1111/cas.14254 · Cited by 66
Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure
Lam, T., Tsang, K. C., Choi, C., Lee, V. H.-F., Lam, K. O., Chiang, C., So, T. H., Chan, W., Nyaw, S. F., Lim, F., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.07.004 · Cited by 68
MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review
Dong, Y., Xu, J., Sun, B., Wang, J., & Wang, Z. (2022) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-021-00568-w · Cited by 67
Directed Discovery of Agents Targeting the Met Tyrosine Kinase Domain by Virtual Screening
Peach, M. L., Tan, N., Choyke, S. J., Giubellino, A., Athauda, G., Burke, T. R., Nicklaus, M. C., & Bottaro, D. P. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm800791f · Cited by 67
Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer
Gower, A., Wang, Y., & Giaccone, G. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1165-y · Cited by 68
Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma patients
Tanaka, A., Sueoka‐Aragane, N., Nakamura, T., Takeda, Y., Mitsuoka, M., Yamasaki, F., Hayashi, S., Sueoka, E., & Kimura, S. H. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.06.004 · Cited by 67
Genetically informed lung cancer medicine
Pao, W. J., Iafrate, A. J., & Su, Z. (2010) · The Journal of Pathology · doi:10.1002/path.2788 · Cited by 69
Self-citation
Effects of Vandetanib on Lung Adenocarcinoma Cells Harboring Epidermal Growth Factor Receptor T790M Mutation In vivo
Ichihara, E., Ohashi, K., Takigawa, N., Osawa, M., Ogino, A., Tanimoto, M., & Kiura, K. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4204 · Cited by 67
ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy
Jaiswal, B. S., Durinck, S., Stawiski, E. W., Yin, J., Wang, W., Lin, E., Moffat, J. G., Martin, S. E., Modrusan, Z. D., & Seshagiri, S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3674 · Cited by 69
Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer
Kuwano, M., Sonoda, K., Murakami, Y., Watari, K., & Ono, M. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.03.002 · Cited by 66
MET targeting: time for a rematch
Koch, J. P., Aebersold, D. M., Zimmer, Y., & Medová, M. (2020) · Oncogene · doi:10.1038/s41388-020-1193-8 · Cited by 66
What’s new in non-small cell lung cancer for pathologists the importance of accurate subtyping, EGFR mutations and ALK rearrangements
Cooper, W. A., O'Toole, S. A., Boyer, M. J., Horvath, L. G., & Mahar, A. M. (2011) · Pathology · doi:10.1097/pat.0b013e328342629d · Cited by 67
EGFR–TKI resistant non-small cell lung cancer (NSCLC): New developments and implications for future treatment
Brugger, W., & Thomas, M. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2011.12.014 · Cited by 66
The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer
Kono, S. A., Marshall, M. E., Ware, K. E., & Heasley, L. E. (2009) · Drug Resistance Updates · doi:10.1016/j.drup.2009.05.001 · Cited by 65
The Evolving Landscape of Resistance to Osimertinib
Schoenfeld, A. J., & Yu, H. A. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.11.005 · Cited by 66
Targeted Therapies in Non-Small Cell Lung Cancer: Emerging Oncogene Targets Following the Success of Epidermal Growth Factor Receptor
Berge, E. M., & Doebele, R. C. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.12.006 · Cited by 65
The resistance mechanisms and treatment strategies for EGFR -mutant advanced non-small-cell lung cancer
Zhong, W., Zhou, Q. H., & Wu, Y.-L. L. C. (2017) · Oncotarget · doi:10.18632/oncotarget.20311 · Cited by 66
Linking somatic genetic alterations in cancer to therapeutics
Stuart, D. D., & Sellers, W. R. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.02.001 · Cited by 66
Mechanisms of resistance to EGFR targeted therapies
Hrustanovic, G., Lee, B. J., & Bivona, T. G. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.23627 · Cited by 67
Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells
Han, S., Zhao, M.-B., Zhuang, G.-B., & Li, P.-P. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.06.001 · Cited by 65
EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts
Lal, B., Goodwin, C. R., Sang, Y., Foss, C. A., Cornet, K., Muzamil, S., Pomper, M. G., Kim, J., & Laterra, J. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0188 · Cited by 65
First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer
He, A. R., Cohen, R. B., Denlinger, C. S., Sama, A. R., Birnbaum, A. E., Hwang, J. J., Sato, T., Lewis, N. L., Mynderse, M., Niland, M., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0411 · Cited by 65
Afatinib Prolongs Survival Compared with Gefitinib in an Epidermal Growth Factor Receptor-Driven Lung Cancer Model
Ninomiya, T., Takigawa, N., Ichihara, E., Ochi, N., Murakami, T., Honda, Y., Kubo, T., Minami, D., Kudo, K., Tanimoto, M., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0885 · Cited by 65
ErbBs in lung cancer
Sharma, S. V., & Settleman, J. E. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.07.026 · Cited by 67
Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion–Positive Advanced NSCLC
van Veggel, B. A. M. H., de Langen, A. J., Hashemi, S. M. S., Monkhorst, K., Heideman, D. A. M., Thunnissen, E., & Smit, E. F. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.04.012 · Cited by 64
NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors
McGowan, M., Kleinberg, L., Halvorsen, A. R., Helland, Å., & Brustugun, O. T. (2017) · Genes & Cancer · doi:10.18632/genesandcancer.136 · Cited by 65
Direct activation of PP2A for the treatment of tyrosine kinase inhibitor–resistant lung adenocarcinoma
Tohmé, R., Izadmehr, S., Gandhe, S., Tabaro, G., Vallabhaneni, S., Thomas, A., Vasireddi, N., Dhawan, N. S., Ma’ayan, A., Sharma, N., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.125693 · Cited by 63
Review of the current targeted therapies for non-small-cell lung cancer
Nguyen, K.-S. H. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i4.576 · Cited by 62
A Decade of Advances in Treatment for Advanced Non–Small Cell Lung Cancer
Gettinger, S. N., & Lynch, T. J. (2011) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2011.08.017 · Cited by 63
In the clinic: ongoing clinical trials evaluating c-MET-inhibiting drugs
Sharma, N., & Adjei, A. A. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834011423403 · Cited by 63
Unique Molecular Landscapes in Cancer: Implications for Individualized, Curated Drug Combinations
Wheler, J. J., Lee, J. J., & Kurzrock, R. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-2329 · Cited by 65
C‐Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectives
Bahrami, A., Shahidsales, S., Khazaei, M., Ghayour‐Mobarhan, M., Maftouh, M., Hassanian, S. M., & Avan, A. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25794 · Cited by 63
Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives
Tomasello, C., Baldessari, C., Napolitano, M., Orsi, G., Grizzi, G., Bertolini, F., Barbieri, F., & Cascinu, S. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.01.013 · Cited by 65
Apoptosis In Targeted Therapy Responses
Faber, A. C., Ebi, H., Costa, C., & Engelman, J. A. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-397927-8.00016-6 · Cited by 63
MET Amplification as a Resistance Driver to TKI Therapies in Lung Cancer: Clinical Challenges and Opportunities
Qin, K., Hong, L., Zhang, J. J., & Le, X. (2023) · Cancers · doi:10.3390/cancers15030612 · Cited by 66
New Insights into the Biology of Renal Cell Carcinoma
Li, L., & Kaelin, W. G. (2011) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2011.04.004 · Cited by 63
Prevalence of driver mutations in non-small-cell lung cancers in the People’s Republic of China
Wu, Y.-L. L. C., & Gou, L.-Y. (2014) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s40817 · Cited by 63
Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer
Kaira, K., Naito, T., Takahashi, T., Ayabe, E., Shimoyama, R., Kaira, R., Ono, A., Igawa, S., Shukuya, T., Murakami, H., et al. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.05.006 · Cited by 61
Porcine Epidemic Diarrhea Virus-Induced Epidermal Growth Factor Receptor Activation Impairs the Antiviral Activity of Type I Interferon
Yang, L., Xu, J., Guo, L., Guo, T., Zhang, L., Feng, L., Chen, H., & Wang, Y. (2018) · Journal of Virology · doi:10.1128/jvi.02095-17 · Cited by 62
CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC
Becker, J. H., Gao, Y., Soucheray, M., Pulido, I., Kikuchi, E., Rodríguez, M. L., Gandhi, R., Lafuente-Sanchis, A., Aupí, M., Fernández-Coronado, J. A., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0024 · Cited by 59
Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib‐resistant non‐small cell lung cancer cells with acquired MET amplification
Yoshida, T., Okamoto, I., Okamoto, W., Hatashita, E., Yamada, Y., Kuwata, K., Nishio, K., Fukuoka, M., Janne, P. A., & Nakagawa, K. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01368.x · Cited by 61
Targeted therapies for advanced non-small-cell lung cancer: Current status and future implications
Custodio, A., Méndez, M., & Provencio, M. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.04.001 · Cited by 62
EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992
Spicer, J. F., & Rudman, S. M. (2010) · Targeted Oncology · doi:10.1007/s11523-010-0140-y · Cited by 61
The Role of EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer
Ray, M., Salgia, R., & Vokes, E. E. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0054 · Cited by 60

Authors: Bean, J., Brennan, C., Shih, J.-Y., Riely, G., Viale, A., Wang, L., Chitale, D., Motoi, N., Szoke, J., Broderick, S., Balak, M., Chang, W.-C., Yu, C.-J., Gazdar, A., Pass, H., Rusch, V., Gerald, W., Huang, S.-F., Yang, P.-C., Miller, V., Ladanyi, M., Yang, C.-H., & Pao, W.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
National Taiwan University (TW)
Department of Pathology, Memorial Sloan–Kettering Cancer Center, New York, NY 10021;
Chang Gung Memorial Hospital (TW)
The University of Texas Southwestern Medical Center (US)
NYU Langone Health (US)
National Health Research Institutes (TW)
National Taiwan University Hospital (TW)
ORCID: Bean, James
Brennan, Cameron
Shih, Jin-Yuan
Riely, Gregory
Viale, Agnes
Wang, Lu
Chitale, Dhananjay
Motoi, Noriko
Broderick, Stephen
Yu, Chong-Jen
Gazdar, Adi
Pass, Harvey
Rusch, Valerie
Huang, Shiu-Feng
Yang, Pan-Chyr
Miller, Vincent
Ladanyi, Marc
Pao, William
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 2007-12-26
Volume: 104
Issue: 52
Pages: 20932-20937
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.0710370104
PMC: PMC2409244
OpenAlex: W2093613683
Cited by: 1,598
References: 37
Citations by year: 2026: 17 · 2025: 19 · 2024: 33 · 2023: 42 · 2022: 59 · 2021: 54 · 2020: 78 · 2019: 78 · 2018: 100 · 2017: 89 · 2016: 116 · 2015: 135 · 2014: 124 · 2013: 148 · 2012: 126
FWCI: 71.72
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Conquer Cancer Foundation
Memorial Sloan-Kettering Cancer Center
Exelixis
National Cancer Institute (U01 CA 84999, P50CA75907, R01CA121210, U01CA084999, K08CA097980, R21CA115051)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: MET amplification, T790M mutation, EGFR mutation, lung adenocarcinoma, acquired drug resistance, gefitinib, erlotinib, EGFR tyrosine kinase inhibitors, copy number alterations, multikinase inhibitor, therapeutic target
MeSH terms: Erlotinib Hydrochloride, Gefitinib, Proto-Oncogene Mas, Adenocarcinoma, Antineoplastic Agents, Chromosomes, Human, Pair 7, DNA Mutational Analysis, Humans, Lung Neoplasms, Mutation, Quinazolines, Cohort Studies, Gene Expression Regulation, Neoplastic, In Situ Hybridization, Fluorescence, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-met, Protein Kinase Inhibitors, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks